INTEREST
Meeting category
Date(s)
5 May 2015 - 8 May 2015
Location
Harare, Zimbabwe
Platinum Level Support
Sponsor logos
Gilead logo
Janssen logo
abbvie

INTEREST 2015

Related Enduring Materials

Enduring Materials

Day 1 - Tuesday, 5 May 2015

Round table: Lessons learned from Ebola for HIV and vice versa -
Responding to an epidemic: perspective from Sierra Leone and Guinea
Peter Kilmarx, MD, FACP, FIDSA
John E. Fogarty International Center, National Institutes of Health, USA
Responding to an epidemic: perspective from Liberia
placeholder3
Brian Hunter
Zimbabwe
Vaccine and drugs pipeline and trials; passive immunization (convalescent serum) and regulatory issues
Peter Kilmarx, MD, FACP, FIDSA
John E. Fogarty International Center, National Institutes of Health, USA
Symposium: AbbVie - Managing HIV in Resource Limited Settings - Growing the Momentum -
Viral load monitoring in RLS: Challenges and lessons; a South African perspective
Francesca Conradie
Francesca Conradie, MBChB (Wits), DTM&H, Dip HIV Man, Dip Epidemiology (LSTMH)
South African Clinicians HIV/AIDS Society, South Africa
Acquired drug resistance in RLS: Causes, patterns and implications
Andrew Kambugu, MB.ChB, MMed, FRCP
Infectious Diseases Institute (IDI), Makerere University, Uganda
Second-line therapies in RLS: Choices and evidence
Nicholas Paton, MD, FRCP
National University of Singapore, Singapore
Session: Prevention of mother-to child transmission (PMTCT) -
Progress and challenges in PMTCT: the unfinished agenda
Chewe Luo, MD, PhD
UNICEF, United States
Satellite Symposium Gilead Sciences Inc. - Debate: Resolved that the Continent of Africa is not yet ready to treat Hepatitis C - State of the Art on Hepatitis -
State of the art on hepatitis C
Mark Nelson, MA, MBBS, FRCP
Chelsea and Westminster Hospital / Imperial College Medical School, United Kingdom
Team affirming the motion
Tapiwanashe Kujinga
Tapiwanashe Kujinga
Zimbabwe
Mark Nelson, MA, MBBS, FRCP
Chelsea and Westminster Hospital / Imperial College Medical School, United Kingdom
Team opposing the motion
Kwasi Torpey, MD, PhD, MPH, FGCP, FWACP
University of Ghana / Amsterdam Institute of Global Health and Development, Ghana / Netherlands
placeholder3
Theobald Owusu-Ansah
Ghana
Official Opening Session -
Official opening
placeholder3
Dr David Parirenyatwa
Minister of Health and Child Care (MHCC), Zimbabwe
HIV in Zimbabwe
Tsitsi Apollo
Tsitsi Apollo
Zimbabwe
Progress in HIV prevention and treatment scale-up in sub-Saharan Africa
placeholder3
Sheila Tlou
UNAIDS
Joep Lange: Lessons for young and early career investigators
Richard Koup
Richard Koup, MD
National Institute of Allergy and Infectious Diseases, USA
Panel Discussion: Remembering Joep Lange and Jacqueline van Tongeren
James Hakim, MBChB, MMed, FRCP, FCP, DSc(HC)
University of Zimbabwe College of Health Sciences (UZCHS), Zimbabwe
Douglas Richman
Douglas Richman, MD
University of California, San Diego, USA
Pauline Byakika
Pauline Byakika, MSc, PhD
Makerere University College of Health Sciences, Uganda
Elly Katabira, MD, FRCP
Makerere University College of Health Sciences, Kampala, Uganda
Moving forward: Building on the legacy
Nicole Spieker
Nicole Spieker, PhD
PharmAccess Foundation, the Netherlands

Day 2 -Wednesday, 6 May 2015

Session: HIV prevention, structural determinants, PrEP -
Female-initiated HIV Prevention Methods: Past, Present and Future
Nyaradzo Mavis Mgodi, MBChB, MMed
University of Zimbabwe Clinical Trials Research Centre, Zimbabwe
Preventing HIV infection in young women – does money matter?
Sinéad Delany-Moretlwe
Sinéad Delany-Moretlwe, MBBCh, PhD
University of the Witwatersrand, South Africa
Refreshment break and poster viewing
PrEP, learning from post-trial and demonstration projects
Kenneth Ngure
Kenneth Ngure, BSc, MPH, EMOD, MSc, PhD
Jomo Kenyatta University of Agriculture and Technology, Kenya
Sponsor Satellite III: Janssen Pharmaceutica NV “I Am Who I Am” – Teens living with HIV -
A Teen’s Story – Living with HIV
A Teen’s Story – Living with HIV
Zimbabwe
Panel Discussion: Support Strategies for Adolescents – What Works?
Rashida Ferrand, FRCP, PhD, FMed Sci
London School of Hygiene & Tropical Medicine, United Kingdom / Biomedical Research and Training Institute, Zimbabwe
Bahati Kasimonje
Bahati Kasimonje
Zimbabwe
Managing ART in Adolescents in 2nd and 3rd Line
Tariro Makadzange
Tariro Makadzange
Gilead Sciences
Margie Pascoe
Margie Pascoe
Margie Pascoe
Zimbabwe
Session: Sex Work, Medication Adherence -
The price of selling sex: HIV among female sex workers—Context and the public health response
Euphemia Sibanda
Euphemia Sibanda, PhD
CeSHHAR Zimbabwe
Medication Adherence: How much is enough?
Terry Blaschke
Terry Blaschke, MD
Stanford University, USA
Session: STI update and new WHO post-exposure prophylaxis guidelines -
Latest findings from Zimbabwe’s ongoing STI etiology study
Kees Rietmeijer
Kees Rietmeijer, PhD, MD, MSPH
Zimbabwe
Update on STI diagnostics, e.g., use of Gene-Xpert for GC/CT testing
Francis Ndowa
Francis Ndowa
Zimbabwe
Implementing the new WHO post-exposure prophylaxis guidelines
François Venter, MD, FCP, PhD
Ezintsha, University of the Witwatersrand, South Africa
Poster Presentations -
Beyond IRIS TB, how common is tuberculosis among patients on ART?
Patrick Katayamoyo
Zambia
Assessing linkage between HIV-testing and care/treatment, by mode of HIV-testing in public hospitals in South-rift Kenya
Jamlick Mutugi M’Muriithi
Kenya
ARISE: Africa Research Initiative and Support – Network
Exnevia Gomo
Exnevia Gomo
Evaluation of the Sysmex-Partec CyFlow® mini-POC against the reference CD4/PLG method in South Africa
Keshendree Moodley
South Africa
Use of Satellite Clinics to Improve the Health Outcomes of HIV Clients at Chilonga MIssin Hospital, Zambia
Ernest Mwila
Zambia
Sex differences in uptake of HIV services in Nigeria: Implications for future programming
Maiya Saleh
Nigeria
Improving PMTCT services through a participatory Continuous Quality Improvement (CQI) approach in Nyanza region of Western Kenya
Margaret Mburu
Kenya
Cervical cancer screening programmes: A case of an antiretroviral access programme in a resource limited setting
Margie Pascoe
Zimbabwe
Debate: PrEP is ready for prime time in Africa -
Team affirming the motion
placeholder3
Sinzo Peter
South Africa
Linda-Gail Bekker, MBChB, DTMH, DCH, FCP(SA), PhD
Desmond Tutu Health Foundation / University of Cape Town (UCT), South Africa
Team opposing the motion
François Venter, MD, FCP, PhD
Ezintsha, University of the Witwatersrand, South Africa
placeholder3
Gaby Gomez
Netherlands

Day 3 - Thursday, 7 May 2015

Session: Antiretroviral therapy and viral load monitoring -
Antiretroviral therapy update: impact of the 2014 WHO guidelines and improving the cascade in resource-limited settings
Nathan Ford
Nathan Ford, MPH, PhD, FRCPE
WHO
Viral load monitoring: Challenges and innovation in laboratory diagnostic implementation
placeholder3
Madisa Mine
Botswana
Session: Paediatrics and cure -
Paediatrics HIV disease
Rashida Ferrand, FRCP, PhD, FMed Sci
London School of Hygiene & Tropical Medicine, United Kingdom / Biomedical Research and Training Institute, Zimbabwe
Reservoirs and HIV Cure in Adults and Children: Insights and Challenges
Caroline Tiemessen
Caroline Tiemessen
National Institute for Communicable Diseases
Session: Voluntary Medical Male Circumcision -
Research update
placeholder3
Mufuta Tshimanga
Zimbabwe
Programmatic progress and challenges: rollout and devices
Karin Hatzold
Karin Hatzold, MD, MPH
Zimbabwe
HIV vaccine strategies
Penny Moore
Penny Moore, PhD
University of the Witwatersrand, South Africa
Discussant
Guido Ferrari
Guido Ferrari, MD
USA
Oral abstracts -
Adherence assessment techniques in adolescents receiving protease inhibitor based antiretroviral therapy in a resource limited setting
Tinashe Mudzviti
Zimbabwe
Delays in confirming suspected treatment failure and in switching to second line antiretroviral therapy in Kenya
John Paul Otieno
Kenya
Pretreatment HIV drug resistance increases regimen switch in sub-Saharan Africa
Bernice Hoenderboom
Netherlands
Retention and long-term virologic outcomes in children and adolescents receiving HIV/ART care at a public sector tertiary level hospital in Zimbabwe
Janneke van Dijk
Zambia
HIV Infection Among Patients With Sexually Transmitted Infections in Zimbabwe
Morblessing Mungati
Zimbabwe
Early Infant Diagnosis Data Transmission System Using Mobile Phones in Zimbabwe
Kenzy Chidawanyika
Zimbabwe
Optimising uptake of PrePex circumcision among adult males through a mobile caravan in Chitungwiza town, Zimbabwe
Pesanai Chatikobo
Zimbabwe
Delays in initiation of antiretroviral therapy among HIV-infected children in rural Zambia
Francis Hamangaba
Zambia
Round table: Treatment as Prevention (TaSP) studies: the challenge of CD4 count treatment eligibility changes in Africa and of PrEP trial and post-trial results. Perspectives from ongoing studies, study design changes, social science insights, challenges -
ANRS TasP, Africa Centre for Health and Population Studies Hlabisa, KZN
Joseph Larmarange
Joseph Larmarange
South Africa
MAX-ART (Swaziland)
Sikhathele Mazibuko
Sikhathele Mazibuko
Swaziland
SEARCH (Uganda and Kenya)
Moses Kamya
Moses Kamya
Uganda
PopART (Zambia and South Africa)
Kalpana Sabapathy
Kalpana Sabapathy
Zambia

Day 4 - Friday, 8 May 2015

Session: HIVDR in the upcoming fight against antimicrobial resistance -
Principles and reality of HIV drug resistance in sub-Saharan Africa
Bruce Richman
Prevention Access Campaign, United States
Long-term effectiveness of ART and HIVDR development in Africa
placeholder3
Kim Sigaloff
Netherlands
Genesis of drug resistance in Tuberculosis in South Africa
placeholder3
Rob Warren
South Africa
Antimalarial Drug Resistance in South Africa: Past, Present and Future!
Jaishree Raman
Jaishree Raman
South Africa
Building laboratory networks and systems to prevent, detect and respond to antimicrobial resistance in Africa
placeholder3
Talkmore Maruta
Zimbabwe
Sponsor Satellite IV: ViiV ART in 2015- have we achieved our goals? Understanding the need to improve 1st and 2nd line treatment going forward -
Approach to management of HIV – understanding the unmet medical needs with our current use of antiretroviral drugs
François Venter, MD, FCP, PhD
Ezintsha, University of the Witwatersrand, South Africa
Has the current management of HIV reached a plateau or can we go further?
Harold Kessler
Harold Kessler
USA
Reflections by the Conference Chairs of the 9th INTEREST Workshop
Overview
Welcome

A very successful 9th INTEREST Workshop, was held in Harare, Zimbabwe 5-8 May 2015, where 472 participants attended the workshop.

The Organizing Committee would like to thank all invited speakers and participants for their contribution to this workshop!

We would like to thank our sponsors AbbVie, Gilead, Janssen, ViiV / GSK, Mylan and MSD for making this event possible.

The INTEREST workshop focuses on issues of particular relevance for the African continent and offers young researchers the opportunity to present their data. The workshop size and atmosphere facilitate discussion and interaction between participants. 9 successful meetings have been convened since INTEREST's inception; in Uganda, Senegal (twice), Zambia (twice), Mozambique, Tanzania, Kenya and Zimbabwe.

The format of the workshop is a 3.5 day program consisting of plenary sessions on HIV prevention and treatment presented by renowned invited speakers, oral abstract presentations, roundtable discussions and poster sessions. Ample time is allocated to Q&A and discussion in order to foster an intimate and interactive workshop.

INTEREST workshop is a collaboration of Virology Education and AIGHD.

Chairs 2015

Chairs 2015
Support
Language